Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1559-1567

  Roland, Peter S ^a   Ryan, Matthew W ^a   Wall, G Michael ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Allergic rhinitis; Allergic rhinosinusitis; Antihistamine; Mast cell stabilizer; Nasal spray; Olopatadine hydrochloride; Patanase Nasal Spray

Indexed keywords

ASTEPRO; AZELASTINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUNISOLIDE; FLUTICASONE FUROATE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE; NASACORT AQ; OLOPATADINE; PATADAY; PATANASE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; AREA UNDER THE CURVE; BITTER TASTE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COUGHING; DERMATITIS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; EPISTAXIS; ERYTHEMA; FATIGUE; HAY FEVER; HUMAN; INFLUENZA; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PERENNIAL RHINITIS; PRURIGO; PRURITUS; PSORIASIS VULGARIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SOMNOLENCE; SORE THROAT; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY TRACT INFECTION; URTICARIA; XEROSTOMIA;

CHILD; CLINICAL TRIALS AS TOPIC; DIBENZOXEPINS; DRUG APPROVAL; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77952687118     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.485609     Document Type: Review

References (38)

1. Levenson T, Greenberger PA. Pathophysiology and therapy for allergic nonallergic rhinitis: an updated review. Allergy Asthma Proc 1997;18:213-220
2. Marshall PS, Colon EA. Effects of allergy season on mood and cognitive function. Ann Allergy 1993;71:251-258
3. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-126
4. Klein GL, Ziering RW, Girsh LS, Miller MF. The allergic irritability syndrome: four case reports and a position statement from the Neuroallergy Committee of the American College of Allergy. Ann Allergy 1985;55:22-24
5. Juniper EF, Guyatt GH, Dolovich J. Clinical aspects of allergic disease: assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-423
6. Meltzer EO, Nathan RA, Selner JC, Storms W. Quality of life and rhinitic symptoms: results of a nationwide survey with the SF-36 and RQLQ questionnaire. J Allergy Clin Immunol 1997;99(Suppl):S815-19
7. Bousquet J, Bullinger M, Fayol C, et al. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Questionnaire. J Allergy Clin Immunol 1994;94:182-188
8. Task Force on Allergic Disorders -- American Academy of Allergy, Asthma and Immunology. The Allergy Report. AAAAI Web Site. Available from: http://www.aaaai.org [Last accessed 13 April 2000]
9. Naclerio R. Pathophysiology of perennial allergic rhinitis. Allergy 1997;52:7-13
10. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518 (Pubitemid 28553778)
11. Bousquet J, Reid J, van Week C, et al. Allergic rhinitis management pocket reference 2008. Allergy 2008;63:990-996
12. Price D, Bond C, Bouchard J, et al. International primary care respiratory group (IPCRG) guidelines: management of allergic rhinitis. Prim Care Respir J 2006;15:58-70
13. Van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-134 (Pubitemid 30106016)
14. Wallace DV, Dykewicz, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008;122:S1-84
15. Patanase- Nasal Spray prescribing information, 2009. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/ 2009/021861s002lbl.pdf [Last accessed 9 December 2009]
16. Yanni JM, Stephens DJ, Miller ST, et al. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergy/ antihistaminic agent. J Ocul Pharmacol Ther 1996;12:256-267
17. Sharif NA, Xu SU, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996;278:1252-1261
18. Ohmori K, Hayashi K, Kaise T, et al. Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol 2002;88:379-397
19. Miyake K, Horikoshi K, Ikeda Y, et al. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J Pharmacol 2001;85:453-456
20. Patel D, Garadi R, Brubaker M, et al. Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate. Allergy Asthma Proc 2007;28:592-599
21. Meltzer EO, Hampel F, Ratner P, et al. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:600-606
22. Ratner PH, Hampel FC, Amar NJ, et al. Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (mountain cedar) allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:474-479
23. Berger WE, Ratner PH, Casale TB, et al. Safety and efficacy of olopatadine hydrochloride nasal spray 0.6% in pediatric subjects with allergic rhinitis. Allergy Asthma Proc 2009;30:612-623
24. Fairchild CJ, Meltzer EO, Roland PS, et al. Comprehensive report of the efficacy, safety, quality of life, and work impact of olopatadine 0.6% and olopatadine 0.4% treatment in patients with seasonal allergic rhinitis. Allergy Asthma Proc 2007;28:1-7
25. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am 2005;25:283-299
26. Stokes M, Amorosi SL, Thompson D, et al. Evaluation of patients' preferences for triamcinolone acetonide aqueous, fluticasone propionate, and mometasone furoate nasal sprays in patients with allergic rhinitis. Otolaryngol Head Neck Surg 2004;131:225-231
27. Herman H. Once-daily administration of intranasal corticosteroids for allergic rhinitis: a comparative review of efficacy, safety, patient preference, and cost. Am J Rhinol 2007;21:70-79
28. Khanna P, Shah A. Assessment of sensory perceptions and patient preference for intranasal corticosteroid sprays in allergic rhinitis. Am J Rhinol 2005;19:316-321
29. Meltzer EO, Garadi R, Laforce C, et al. Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc 2008;29:659-668
30. Greiner AN. Allergic rhinitis: impact of the disease and considerations for management. Med Clin North Am 2006;90:17-38
31. Astelin [Package Insert]. Somerset, NJ: MedPointe Pharmaceuticals, MedPointe Healthcare, Inc., 2006
32. Kaliner MA, Storms W, Tilles S, et al. Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50?g in the treatment of seasonal allergic rhinitis. Allergy Asthma Proc 2009;30:255-262
33. Waddell AN, Patel SK, Toma AG, Maw AR. Intransal seteroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 2003;117:843-845
34. Koepke JW, Beaucher WN, Kobayashi RH, et al. Long-term safety and efficacy of triamcinolone acetonide aqueous nasal spray for the treatment of perennial allergic rhinitis. Allergy Asthma Proc 1997;18:33-37
35. VERAMYST Nasal Spray Prescribing Information 2009. Available from: http://www. accessdata.fda.gov/drugsatfda-docs/label/ 2007/022051lbl.pdf [Last accessed 22 May 2009]
36. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136:S107-24
37. Kaliner MA. A novel and effective approach to treating rhinitis with nasal antihistamines. Ann Allergy Asthma Immunol 2007;99:383-391
38. Corren J, Storms W, Bernstein J, et al. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543-553